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Interventional Cardiology
Switching From Heparin or Enoxaparin
to Bivalirudin Reduces Bleeding Complications
The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY)trial demonstrated that bivalirudin reduced bleeding complications compared to
both unfractionated heparin (UFH) and enoxaparin plus a glycoprotein IIb/IIIa
inhibitor in patients having intervention. However, there is concern that switching
from one regimen to another may increase bleeding complications. In the ACUITY
trial, patients switched tobivalirudinhad similar rates of ischemia, butwereonlyone-half as
likely to have major bleeding as those who remained on UFH/enoxaparin. Similar results
were found in patients who were not pre-treated with UFH or enoxaparin. These results
suggest that bivalrudin consistently reduces bleeding complications and may
be used even when patients have already received either UFH or enoxaparin.
See page 1734. See figure.
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Vascular Disorders
Statins Appear to Be Beneficial for Coronary Spasm
Recent evidence suggests that endothelial dysfunction is important for the patho-physiology of coronary spasm. The SCAST (Statin and Coronary Artery Spasm
Trial) studied 64 patients who had spasm provoked by the intracoronary administra-
tion of acetylcholine (Ach). Subjects were then treated with a calcium-channel blocker
and one-half were randomized to also receive fluvastatin. The Ach challenge was
repeated after 6 months. Fluvastatin significantly reduced the number of coronary
segments with induced spasm. The addition of fluvastatin appears to reduce coronary
spasm although the mechanism is unclear. See page 1742. See figure.
Vascular Disorders
Significant Interactions Found Between Endothelium and Thrombin Receptor
Thrombin is central to the coagulation cascade and also induces vascular effects viaprotease-activated receptor type 1 (PAR-1). Gu mundsdo´ttir and colleagues
performed a series of elegant experiments to identify the effects of thrombin on the
vasculature using SFLLRN which is a peptide that mimics activation of the PAR-1
receptor. The PAR-1 activation was found to induce arterial vasodilation, which
required a functioning endothelium, and venoconstriction, which was endothelium
independent. These findings provide evidence of a major interaction between the
endothelium and thrombin in vivo. See page 1749.
(continued) A-32Heart Failure
Obesity and Inflammation Predict Risk of New Onset CHF
Although obesity is considered a risk factor for congestive heart failure (CHF), themechanisms remain unclear. Bahrami and colleagues used data from the MESA
(Multi-Ethnic Study of Atherosclerosis) study to identify risk factors for new onset
CHF. The absolute risk of CHF in nonobese participants was 10 in 1,000, this risk
increased to 16 in 1,000 for obese participants. While obesity was associated with
incident CHF, this association was no longer significant after adding inflammatory
markers (interleukin-6 or C-reactive protein) to themultivariablemodel. These results
suggest that the link between obesity and CHFmay be higher levels of inflammation.
See page 1775.
Heart Rhythm Disorders
Atrial Fibrillation Leads to Prothrombotic State
In order to determine whether atrial fibrillation (AF) causes platelet activation, Akarand colleagues collected blood samples from the coronary sinus of patients before
and after 15min of intentionally inducedAF.These resultswere compared to a control
group that underwent right atrial pacing without inducing AF. In AF patients, but not
controls, there was increased platelet expression of P-selectin, increased thrombin
production, and decreased nitric oxide formation. These findings show that AF causes
local cardiac platelet activationwithinminutes of onset and demonstrates howAFmay
contribute to a hypercoagulable state. See page 1790.
